M
Moderna, Inc. (MRNA)
NMS – Real vaqt narxi. Valyuta: USD
53.27
+0.39 (0.74%)
Yopilishda: May 12, 2026, 4:00 PM EDT
53.39
+0.12 (0.23%)
Bozordan keyin: May 12, 2026, 7:58 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
53.27
+0.39 (0.74%)
Yopilishda: May 12, 2026, 4:00 PM EDT
53.39
+0.12 (0.23%)
Bozordan keyin: May 12, 2026, 7:58 PM EDT
Moderna, Inc., biotexnologiya kompaniyasi, Qo'shma Shtatlar, Yevropa va xalqaro miqyosda mRNK dori vositalarini taqdim etadi. Kompaniyaning respiratorli vaktsinalari spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, mavsumiy gripp, kombinatsiyalangan va pandemik gripp vaktsinalarini o'z ichiga oladi; latent vaktsinalar sitomegalovirus, Ebsteyn-Barr virusi va OITS virusi vaktsinalarini o'z ichiga oladi; ichak viruslari norovirusni o'z ichiga oladi; jamoat salomatligi vaktsinalari Zika, Nipah va Mpox vaktsinalarini o'z ichiga oladi; va Lyme kasalligi vaktsinalari kabi bakterial kasalliklarga qarshi vaktsinalar. Shuningdek, u intismeran autogene, saraton antigen terapiyasi, t-hujayrali ingiger va hujayra terapiyasi kuchaytirgichi kabi onkologik terapiyani; va propion va metilmalonik asidemiya, va kistoz fibroz kabi kam uchraydigan kasalliklar uchun mahsulotlarni taqdim etadi. U Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Mudofaa ilg'or tadqiqotlar loyihalari agentligi; Biomeditsina ilg'or tadqiqot va rivojlantirish boshqarmasi; Hayotni o'zgartiruvchi dorilar instituti; Bill va Melinda Geyts fondi; va OpenAI bilan strategik ittifoqlar va hamkorliklarga ega. Kompaniya ilgari Moderna Therapeutics, Inc. nomi bilan tanilgan va 2018-yil avgust oyida Moderna, Inc. nomini olgan. Moderna, Inc. 2010-yilda tashkil etilgan va shtab-kvartirasi Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Charbel Haber M.P.H., Ph.D. | Senior VP & Head of Global Regulatory Science |
| Dr. Jerh Collins Ph.D. | Chief Technical Operations & Quality Officer |
| Dr. John Lepore J.D., M.D. | Senior Vice President of Government Engagement |
| Dr. Stephen Hoge M.D. | President |
| Mr. James M. Mock | Chief Financial Officer |
| Mr. Patrick Norman Bergstedt | Senior Vice President of Commercial Vaccines |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-11 | 8-K | mrna-20260506.htm |
| 2026-05-01 | 10-Q | mrna-20260331.htm |
| 2026-03-16 | DEFA14A | moderna2026defa14a.htm |
| 2026-03-16 | ARS | mrna014719-ars.pdf |
| 2026-03-05 | 8-K | mrna-20260303.htm |
| 2026-02-20 | 10-K | mrna-20251231.htm |
| 2026-02-13 | 8-K | mrna-20260213.htm |
| 2026-02-11 | 8-K | mrna-20260203.htm |
| 2026-01-12 | 8-K | mrna-20260112.htm |
| 2026-01-05 | 8-K | mrna-20260105.htm |
| Mr. Stéphane Bancel M.B.A. | CEO & Director |
| Ms. Lavina Talukdar CFA | Senior VP & Head of Investor Relations |
| Ms. Shannon Thyme Klinger J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Tracey Franklin | Chief People & Digital Technology Officer |